Literature DB >> 22522789

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.

E Van Valckenborgh, E Schouppe, K Movahedi, E De Bruyne, E Menu, P De Baetselier, K Vanderkerken, J A Van Ginderachter.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22522789     DOI： 10.1038/leu.2012.113

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  38 in total

Review 1.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

Authors:  Zhiwu Tan; Li Liu; Mei Sum Chiu; Ka-Wai Cheung; Chi Wing Yan; Zhe Yu; Boon Kiat Lee; Wan Liu; Kwan Man; Zhiwei Chen
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 3.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

Review 4.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

5.  Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Authors:  Maria Ozerova; Yulia Nefedova
Journal:  Leuk Lymphoma       Date:  2019-01-02

6.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.

Authors:  A Romano; N L Parrinello; M L Consoli; L Marchionni; S Forte; C Conticello; A Pompa; A Corso; G Milone; F Di Raimondo; I Borrello
Journal:  Ann Hematol       Date:  2015-07-31       Impact factor: 3.673

Review 8.  Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Authors:  Chuang Sun; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

Review 9.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

Review 10.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.